Russell Frank Company’s Lexicon Pharmaceuticals LXRX Stock Holding History

Russell Frank Company’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$1.94M	Buy	162,369 +135,759	+510%	+$1.42M	﹤0.01%	1866
2015 Q4	$356K	Sell	26,610 -829	-3%	-$10.2K	﹤0.01%	2568
2015 Q3	$295K	Sell	27,439 -31,066	-53%	-$339K	﹤0.01%	2633
2015 Q2	$471K	Buy	+58,505	New	+$430K	﹤0.01%	2596
2015 Q1	–	Sell	-8,043	Closed	-$49K	–	3006
2014 Q4	$49K	Buy	+8,043	New	+$64.8K	﹤0.01%	2802
2013 Q4	–	Sell	-2,368	Closed	-$39K	–	2933
2013 Q3	$39K	Buy	2,368 +623	+36%	+$10.4K	﹤0.01%	3154
2013 Q2	$26K	Buy	+1,745	New	+$26.5K	﹤0.01%	2969

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Russell Frank Company's LXRX Position: Q1 2016 in Review

Russell Frank Company increased its Lexicon Pharmaceuticals (LXRX) stake by 510% in Q1 2016, buying an estimated $1.42M and bringing the position to 162,369 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1866.

Russell Frank Company first reported a position in LXRX in Q2 2013 and has held it in 7 quarters since. 132 funds tracked by Wall St. Rank hold LXRX as of Q1 2016.

Russell Frank Company held 162,369 shares of Lexicon Pharmaceuticals worth $1.94M as of Q1 2016.
Russell Frank Company bought 135,759 Lexicon Pharmaceuticals shares in Q1 2016, an estimated $1.42M.
Lexicon Pharmaceuticals made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #1866 holding.
Russell Frank Company first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 7 quarters since.
132 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.